^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SMART 102

    i
    Other names: SMART 102, Human T Lymphoid Progenitor (HTLP) injection, human T lymphoid progenitor cell therapy
    Associations

    News

    Trials
    Company:
    Public Assistance - Paris Hospitals, Smart Immune
    Drug class:
    Cell therapy
    Related drugs:
    Associations

    News

    Trials
    6ms
    Human Pro-T-Cell Manufacturing in Vitro Is a Safe Procedure for Hematopoietic Stem Cell Transplantation with Delayed T-Cell Reconstitution: Interim Results from 2 Different Clinical Trials (ASH 2023)
    The GMP generation of Human T lymphoid Progenitors (HTLP) that are competent to rapidly become in vivo differentiated functional and thymic-educated T-cells may overcome the post-transplant delayed immune reconstitution... First infusions of HTLP in both clinical trials confirmed the safety and reproducible GMP manufacturing. HLTP offers an exciting perspective for improving immune reconstitution in alternative hematopoietic transplants.
    Preclinical
    |
    CD34 (CD34 molecule) • CD7 (CD7 Molecule)
    |
    SMART 102